# US 2011/0237794 A1 · Spiro Compounds And Methods Of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0237794 A1
- Document ID: US20110237794A1
- Status: Published application
- Kind: A1
- Application number: 13/151,251
- Filed: 2011-06-01
- Published: 2011-09-29
- Earliest claimed: 2006-12-30
- Inventors: GUOQING PAUL CHEN
- Web page: https://patentgrep.com/patent/US20110237794A1

## CPC

- C07D 209/96: Spiro-condensed ring systems
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 491/20: Spiro-condensed systems
- C07D 497/10: Spiro-condensed systems
- C07D 498/20: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to spiro compounds of formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states such as cancers associated with protein tyrosine kinases, especially epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), to their method of use as medicaments and to their method of use in the manufacture of medicaments for use in the production of inhibition of tyrosine kinase reducing effects in warm-blooded animals such as humans.

## Claims

### Claim 1

A Spiro compound of formula I
Wherein
a is 1, 2, 3, 4 or 5;
b and c are each independently 1, 2, or 3;
When X and Y are selected from (i) X combines Y to be an oxygen or methylene, (ii) X is hydrogen, Y is hydrogen, (iii) X is hydrogen, Y is hydroxy or its optical isomer; R′ and R″ are not presented;
When X and Y are selected from (iv) X is hydrogen, Y is O, S or its optical isomer position, (v) X and Y are both O or S, or (vi) X is O and Y is S; R′ and R″ are each independently halogeno-lower alkyl, lower alkyl, lower alkoxy, hydroxy, lower alkylhydroxy; optionally R′ and R″ combine to form a 5 to 7 membered ring with X, Y and the spiro carbon which ring, may be unsubstituted or substituted independently by up to three substituents;
R is selected from:
Ra is selected from lower alkylenyl, lower alkenlenyl or lower alkynlenyl;
Rb is selected from halogen, hydroxy, methanesulfonate, toluenesulfonate, aryl or heterocyclyl;
W is selected from O, S, —NR, or —CHRc;
G is selected from —C—CN or —CRc;
Z is selected from O, S, —NRd or —CHRd;
Rc is selected from H, lower alkyl;
Rd is selected from H, lower alkyl, amino or alkylamino;
R1, R3, and R4 are each independently selected from H, halogen, halogeno-lower alkyl, lower alkyl, lower alkoxy, lower alkoxyalkoxy, lower alkenyl, or lower alkynyl;
R2 is selected from H, halogen, halogeno-lower alkyl or lower alkyl;
Or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of Formula I according to claim 1, wherein
a is 1, 2, 3, 4 or 5;
b and c are each independently 1, 2, or 3;
When X and Y are selected from (i) X combines Y to be an oxygen or methylene, (ii) X is hydrogen, Y is hydrogen, (iii) X is hydrogen, Y is hydroxy or its optical isomer; R′ and R″ are not presented; these moieties are selected from ketone, methylene as well as hydroxy and its optical isomers;
When X and Y are selected from (iv) X is hydrogen, Y is O, S or its optical isomer position, (v) X and Y are both O or S, or (vi) X is O and Y is S; R′ and R″ are each independently halogeno-lower alkyl, lower alkyl, lower alkoxy, hydroxy, lower alkylhydroxy; optionally R′ and R″ combine to form a 5 to 7 membered ring with X, Y and the spiro carbon which ring, may be unsubstituted or substituted independently by up to three substituents;
R is selected from:
Ra is selected from lower alkylenyl, lower alkenlenyl or lower alkynlenyl;
Rb is selected from halogen, hydroxy, methanesulfonate, toluenesulfonate, aryl or heterocyclyl;
W is selected from O, S, —NR, or —CHRc;
G is selected from —C—CN or —CRc;
Z is selected from O, S, —NRd or —CHRd;
Rc is selected from H, lower alkyl;
Rd is selected from H, lower alkyl, amino or alkylamino;
R1, R3, and R4 are each independently selected from H, halogen, halogeno-lower alkyl, lower alkyl, lower alkoxy, lower alkoxyalkoxy, lower alkenyl, or lower alkynyl;
R2 is selected from H, halogen, halogeno-lower alkyl or lower alkyl;
Or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of Formula I according to claim 1, wherein
a is 1;
b and c are each independently 1;
When X and Y are selected from (i) X combines Y to be an oxygen or methylene, (ii) X is hydrogen, Y is hydrogen, (iii) X is hydrogen, Y is hydroxy or its optical isomer; R′ and R″ are not presented; these moieties are selected from ketone, methylene as well as hydroxy and its optical isomers;
When X and Y are selected from (iv) X is hydrogen, Y is O, S or its optical isomer position, (v) X and Y are both O or S, or (vi) X is O and Y is S; R′ and R″ are each independently halogeno-lower alkyl, lower alkyl, lower alkoxy, hydroxy, lower alkylhydroxy; optionally R′ and R″ combine to form a 5 to 7 membered ring with X, Y and the spiro carbon which ring, may be unsubstituted or substituted independently by up to three substituents;
R is selected from:
Ra is lower alkylenyl;
Rb is halogen or hydroxy;
W is selected from O, S, —NR, or —CHRc;
G is selected from —C—CN or —CRc;
Z is selected from O, S, —NRd or —CHRd;
Rc is selected from H, lower alkyl;
Rd is selected from H, lower alkyl, amino or alkylamino;
R1, R3, and R4 are each independently selected from H, halogen, halogeno-lower alkyl, lower alkyl, lower alkoxy, lower alkoxyalkoxy, lower alkenyl, or lower alkynyl;
R2 is selected from H, halogen, halogeno-lower alkyl or lower alkyl;
Or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of Formula I according to claim 1, wherein
a is 1;
b and c are each independently 1;
When X and Y are selected from (i) X combines Y to be an oxygen or methylene, (ii) X is hydrogen, Y is hydrogen, (iii) X is hydrogen, Y is hydroxy or its optical isomer; R′ and R″ are not presented; these moieties are selected from ketone, methylene as well as hydroxy and its optical isomers;
When X and Y are selected from (iv) X is hydrogen, Y is O, S or its optical isomer position, (v) X and Y are both O or S, or (vi) X is O and Y is S; R′ and R″ are each independently halogeno-lower alkyl, lower alkyl, lower alkoxy, hydroxy, lower alkylhydroxy; optionally R′ and R″ combine to form a 5 to 7 membered ring with X, Y and the spiro carbon which ring, may be unsubstituted or substituted independently by up to three substituents;
R is selected from:
Ra is lower alkylenyl;
Rb is halogen or hydroxy.

### Claim 5 (depends on 1)

A compound of Formula I according to claim 1 selected from:
R is selected from:

### Claim 6 (depends on 1)

A compound of Formula I according to claim 1 selected from:
10-(2-hydroxyethyl)-5,8-Dioxa-10-azadispiro[2.0.4.3]undecane
10-(3-hydroxypropyl)-5,8-Dioxa-10-azadispiro[2.0.4.3]undecane
5-(2-hydroxyethyl)-5-azaspiro[2.4]heptan-7-one
5-(3-hydroxypropyl)-5-azaspiro[2.4]heptan-7-one
5-(2-hydroxyethyl)-5-azaspiro[2.4]heptan-7-ol
5-azaspiro[2.4]heptan-7-ol
2-(5-azaspiro[2.4]heptan-5-yl)ethanol
3-(5-azaspiro[2.4]heptan-5-yl)propan-1-ol
5-benzyl-7-methoxy-5-azaspiro[2.4]heptane
7-methoxy-5-azaspiro[2.4]heptane
10-benzyl-5,8-Oxathiolane-10-azadispiro[2.0.4.3]undecane
5,8-Oxathiolane-10-azadispiro[2.0.4.3]undecane
5,9-Dioxa-11-azadispiro[2.0.4.3]dodecane
5,9-Dioxa-7,7-dimethyl-11-azadispiro[2.0.4.3]dodecane
11-(2-hydroxyethyl)-5,9-Dioxa-11-azadispiro[2.0.4.3]dodecane
11-(2-hydroxyethyl)-5,9-Dioxa-7,7-dimethyl-11-azadispiro[2.0.4.3]dodecane
10-(3-amino-5-trifluoro-phenyl)-5,8-Dioxa-10-azadispiro[2.0.4.3]undecane
5-(3-amino-5-trifluoro-phenyl)-5-azaspiro[2.4]heptan-7-one
5-(3-amino-5-trifluoro-phenyl)-5-azaspiro[2.4]heptan-7-ol
5-benzyl-7-methylene-5-azaspiro[2.4]heptane
7-methylene-5-azaspiro[2.4]heptane.
